In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 201 to 217 of 217

Sort by

Keyword or reference number: Treating this as aRemove Keyword or reference number: Treating this as a filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351	Technology appraisal guidance	TBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]	Technology appraisal guidance	TBC
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over ID6557	Technology appraisal guidance	TBC
Transvenous embolisation for treating cerebrospinal fluid-venous fistula associated with spontaneous intracranial hypotension	Interventional procedures guidance	25 March 2026
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]	Technology appraisal guidance	TBC
Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]	Technology appraisal guidance	TBC
Upadacitinib for treating giant cell arteritis [ID6299]	Technology appraisal guidance	TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]	Technology appraisal guidance	TBC
VER-01 for treating chronic low back pain [ID6638]	Technology appraisal guidance	TBC
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099	Technology appraisal guidance	TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]	Technology appraisal guidance	TBC
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]	Technology appraisal guidance	28 January 2026
Vosoritide for treating achondroplasia in people 4 months and over [ID6488]	Technology appraisal guidance	TBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]	Highly specialised technology	TBC
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]	Technology appraisal guidance	14 May 2026
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]	Technology appraisal guidance	TBC
Zuranolone for treating postnatal depression [ID6431]	Technology appraisal guidance	TBC

Results per page

10
25
50
All